Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices: A Multicenter, Retrospective, Propensity-Matched Comparison of Evolut PRO Versus Acurate neo Transcatheter Heart Valves.

Pagnesi, Matteo; Kim, Won-Keun; Conradi, Lenard; Barbanti, Marco; Stefanini, Giulio G; Zeus, Tobias; Pilgrim, Thomas; Schofer, Joachim; Zweiker, David; Testa, Luca; Taramasso, Maurizio; Hildick-Smith, David; Abizaid, Alexandre; Wolf, Alexander; Van Mieghem, Nicolas M; Sedaghat, Alexander; Wöhrle, Jochen; Khogali, Saib; Van der Heyden, Jan A S; Webb, John G; ... (2019). Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices: A Multicenter, Retrospective, Propensity-Matched Comparison of Evolut PRO Versus Acurate neo Transcatheter Heart Valves. JACC. Cardiovascular Interventions, 12(5), pp. 433-443. Elsevier 10.1016/j.jcin.2018.11.036

[img] Text
Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (413kB) | Request a copy

OBJECTIVES

The aim of this study was to compare transcatheter aortic valve replacement (TAVR) with the Acurate neo (NEO) and Evolut PRO (PRO) devices.

BACKGROUND

The NEO and PRO bioprostheses are 2 next-generation self-expanding devices developed for TAVR.

METHODS

The NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) registry retrospectively included patients who underwent transfemoral TAVR with either NEO or PRO valves at 24 centers between January 2012 and March 2018. One-to-one propensity score matching resulted in 251 pairs. Pre-discharge and 30-day Valve Academic Research Consortium (VARC)-2 defined outcomes were evaluated. Binary logistic regression was performed to adjust the treatment effect for propensity score quintiles.

RESULTS

A total of 1,551 patients (n = 1,263 NEO; n = 288 PRO) were included. The mean age was 82 years, and the mean Society of Thoracic Surgeons score was 5.1%. After propensity score matching (n = 502), VARC-2 device success (90.6% vs. 91.6%; p = 0.751) and pre-discharge moderate to severe (II+) paravalvular aortic regurgitation (7.3% vs. 5.7%; p = 0.584) were comparable between the NEO and PRO groups. Furthermore, there were no significant differences in any 30-day clinical outcome between matched NEO and PRO pairs, including all-cause mortality (3.2% vs. 1.2%; p = 0.221), stroke (2.4% vs. 2.8%; p = 1.000), new permanent pacemaker implantation (11.0% vs. 12.8%; p = 0.565), and VARC-2 early safety endpoint (10.6% vs. 10.4%; p = 1.000). Logistic regression on the unmatched cohort confirmed a similar risk of VARC-2 device success, paravalvular aortic regurgitation II+, and 30-day clinical outcomes after NEO and PRO implantation.

CONCLUSIONS

In this multicenter registry, transfemoral TAVR with the NEO and PRO bioprostheses was associated with high device success, acceptable rates of paravalvular aortic regurgitation II+, and good 30-day clinical outcomes. After adjusting for potential confounders, short-term outcomes were similar between the devices.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Pilgrim, Thomas, Asami, Masahiko, Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1876-7605

Publisher:

Elsevier

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

12 Feb 2020 10:41

Last Modified:

05 Dec 2022 15:35

Publisher DOI:

10.1016/j.jcin.2018.11.036

PubMed ID:

30846081

Uncontrolled Keywords:

Acurate neo Evolut PRO TAVR VARC-2 self-expanding

BORIS DOI:

10.7892/boris.139156

URI:

https://boris.unibe.ch/id/eprint/139156

Actions (login required)

Edit item Edit item
Provide Feedback